Previous 10 | Next 10 |
Gainers: Silk Road Medical (SILK) +12%. Clene (CLNN) +6%. BioCardia (BCDA) +2%. Veru (VERU) +2%. ERYTECH Pharma (ERYP) +1%. Losers: Global Cord Blood (CO) -28%. Zosano Pharma (ZSAN) -21%. Vaxxinity (VAXX) -17%. HUTCHMED (China) (HCM)...
We are seeing a perplexing amount of insider buying in housing related companies. The CEO of mortgage originator Rocket Companies bought shares this week. An interesting insider purchase this week was by a Director of retail REIT CBL & Associates, which emerged from bankruptcy...
Shares of nanotherapeutic concern Clene Inc. (CLNN) are down some 75% from its first trade as a public company back in December 2020. The company’s lead asset (CNM-Au8) flunked a Phase 2 ALS trial on primary and secondary endpoints but other exploratory data suggest potential f...
Clene (NASDAQ:CLNN) reported new data from the extension part of a phase 2 trial of CNM-Au8 in patients with early amyotrophic lateral sclerosis (ALS). The company said the data showed a 70% survival benefit among patients with ALS who entered the open-label extension of the phase 2...
SALT LAKE CITY, April 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative d...
The following slide deck was published by Clene Inc. in conjunction with this event. For further details see: Clene (CLNN) Investor Presentation - Slideshow
Clene (NASDAQ:CLNN) reported updated data from two phase 2 trials, RESCUE-ALS and REPAIR evaluating CNM-Au8. The RESCUE-ALS trial evaluated CNM-Au8 in 45 people with early amyotrophic lateral sclerosis (ALS). The company said that after 36 weeks of treatment there were signifi...
Analyses of long-term open-label extension of RESCUE-ALS trial indicate improved survival compared to predictions derived from validated ENCALS risk model Interim results demonstrate approximately 70% decreased risk of death for participants who entered the RESCUE-ALS long-term op...
Clene press release (NASDAQ:CLNN): FY GAAP EPS of -$0.16 beats by $0.24. Revenue of $0.72M (+242.9% Y/Y) beats by $0.12M. For further details see: Clene GAAP EPS of -$0.16 beats by $0.24, revenue of $0.72M beats by $0.12M
Cash and restricted cash of $50.3 million as of December 31, 2021 Visionary-MS Phase 2 Trial unblinded results expected 2H 2022 Healey ALS Platform Trial top-line data expected 2H 2022 COVID-19 Phase 2 Trial top-line results expected mid-year 2022...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...